A comparison of the efficacy of the Adductor-Canal-Blockade vs. the femoral nerve block on muscle strength and mobilization in healthy volunteers: a randomized study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-004285-15-DK

Enrollment

Registered

2011-09-07

Start date

2011-09-22

Completion date

Unknown

Last updated

2016-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers (intended for postoperative pain treatment in patients after total knee arthroplasty) MedDRA version: 14.0 Level: LLT Classification code 10054711 Term: Postoperative pain System Organ Class: 10022117 - Injury, poisoning and procedural complications

Interventions

Trade Name: Ropivacain Product Name: Ropivacain Pharmaceutical Form: Solution for injection INN or Proposed INN: ropivacain CAS Number: 98717-15-8 Other descriptive name: ROPIVACAINE HYDROCHLORIDE Con

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Age 18-30 years - Men - ASA 1 - BMI 18-25 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 12 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Allergy to study medication - Earlier trauma or surgery to lower limbs - Diabetes Mellitus

Design outcomes

Primary

Measure	Time frame
Main Objective: Our aim is to compare the effect of the Adductor-Canal-Blockade versus the femoral nerve block on muscle strength in healthy volunteers. Our hypothesis is that the Adductor-Canal-Blockade in a lesser degree compromises muscle strength compared to the femoral nerve block.;Secondary Objective: Our aim is to compare the effect of the Adductor-Canal-Blockade versus the femoral nerve block on mobilization in healthy volunteers. Our hypothesis is that the Adductor-Canal-Blockade in a lesser degree compromises mobilization compared to the femoral nerve block.;Primary end point(s): Difference in muscle strength between the Adductor-Canal-Blockade and the placebo group;Timepoint(s) of evaluation of this end point: Area under the curve (AUC) 30 minutes -6 hours	—

Measure

Time frame

Main Objective: Our aim is to compare the effect of the Adductor-Canal-Blockade versus the femoral nerve block on muscle strength in healthy volunteers. Our hypothesis is that the Adductor-Canal-Blockade in a lesser degree compromises muscle strength compared to the femoral nerve block.;Secondary Objective: Our aim is to compare the effect of the Adductor-Canal-Blockade versus the femoral nerve block on mobilization in healthy volunteers. Our hypothesis is that the Adductor-Canal-Blockade in a lesser degree compromises mobilization compared to the femoral nerve block.;Primary end point(s): Difference in muscle strength between the Adductor-Canal-Blockade and the placebo group;Timepoint(s) of evaluation of this end point: Area under the curve (AUC) 30 minutes -6 hours

—

Secondary

Measure	Time frame
Secondary end point(s): Difference in muscle strength between the Adductor-Canal-Blockade and the femoral nerve group Difference in muscle strength between the placebo and the femoral nerve group Difference in the mobilization tests between the groups;Timepoint(s) of evaluation of this end point: Muscle strength: Area under the curve (AUC) 30 minutes -6 hours Mobilization tests: 1 and 6 hours	—

Countries

Denmark

Contacts

Public ContactClinical Trials Information

Rigshospitalet

pia.jaeger@rh.regionh.dk004535453487

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026